Veterinary Therapeutic Protein and Peptide High Throughput Screening

R&D Solutions

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veterinary Therapeutic Protein and Peptide High Throughput Screening

Inquiry Now

HTS Assay Services Technologies Service Workflow Related Research Why Choose Us? Case Study FAQs

BioVenic offers high-throughput screening (HTS) services for the rapid identification and evaluation of candidate therapeutic proteins and peptides, supporting discovery and preclinical development across livestock, poultry, aquaculture, companion animals, and economically important insects. Our platform covers a broad range of assay formats—cell-based assays, enzyme activity, molecular binding (SPR, ITC, fluorescence polarization), protein-protein interaction (co-IP, FRET/BRET, AlphaScreen, yeast two-hybrid), gene expression, and compound library screening—alongside microarray, immobilization, and other advanced detection technologies (FRET, ELISA, MS, HCS). We support customized, automated screening workflows from target identification and assay design through hit screening of extensive compound libraries, delivering detailed analyses and report-ready candidate shortlists with high efficacy and stability.

Protein and Peptide HTS Assay Services

BioVenic has a comprehensive HTS assay platform for veterinary therapeutic protein and peptide discovery, with a strict quality control process to ensure effectiveness and efficiency. Our system is capable of preparing, incubating, and analyzing numerous plates at the same time, significantly reducing the time scale of protein and peptide discovery, as well as minimizing the labor required, and accelerating the data-collection process. Below are some of the services offered within our HTS assay system.

HTS Assay Methods	Description	Services
Cell-based Assays	Cells can be employed to serve as readouts for cell-based assays as an alternative or complement to biochemical assays for high-throughput screening in veterinary therapeutic protein and peptide discovery.	Perform cell-based assays to measure the biological activity of candidates in living cells. Use the data obtained to study the bioactivity, mechanism of action, and drug ability of protein/peptide compounds.
Enzyme Activity Assays	This method measures the catalytic activity of enzymes by quantifying the rate at which an enzyme converts a substrate (protein or peptide) into a product.	Conduct enzyme activity assays to measure the activity of specific enzymes in the presence of test compounds (proteins or peptides). Use colorimetric, fluorescent, or luminescent methods to detect substrate conversion, and identify inhibitors or activators of enzyme targets.
Molecular Binding Assays	It detects the interaction between two molecules, typically a ligand (such as a protein/peptide) and its target (such as a protein).	Characterize the binding affinity and kinetics of ligand-receptor interactions. Study the molecular mechanisms underlying binding events. Techniques including surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and fluorescence polarization, are provided for offering insights into binding affinity and kinetics.
Protein-protein Interactions	This technology is designed to determine the interactions between two or more proteins.	Assist clients in discovering the potential drug targets by understanding protein interaction. Methods like co-immunoprecipitation, FRET/BRET, AlphaScreen, and yeast two-hybrid systems are offered.
Gene Expression Screening	Based on next-generation sequencing, this technology involves measuring changes in gene expression levels in response to various treatments or conditions.	Perform gene expression screening to evaluate the impact of compounds(proteins/peptides) on gene transcription levels.
Compound Library Screening	It involves testing a large number of veterinary therapeutic proteins or peptides to identify those that have a desired biological effect.	Conduct high-throughput screening of large compound libraries to identify hits with desired biological activities. Integrate various assay types to identify potential therapeutic candidates from vast libraries.

Protein and Peptide HTP Technologies

Microarrays
Peptide microarray screening involves arranging thousands to millions of different short-chain peptides on a fixed surface, while protein microarrays contain a large number of different proteins. These microarrays are used to test the interactions of peptides or proteins with other molecules. BioVenic offers veterinary therapeutic protein and peptide microarray screening services, utilizing high-throughput screening to rapidly filter candidate molecules and identify proteins and peptides with specific biological activities.

Fig.1 The study of protein-protein/peptide molecule interactions using protein microarrays. (BioVenic Original) Fig.1 Protein microarrays for protein-protein/peptide molecules interaction study. (BioVenic Original)

Immobilization
The choice of material used as a solid support is one of the critical determinants of array performance. BioVenic provides common surfaces such as nitrocellulose membranes and polyvinylidene difluoride (PVDF) membranes for microarray fabrication that immobilize proteins and peptides and maintain their conformation. For the preparation of arrays with already synthesized proteins or peptides, there are generally three methods for immobilizing proteins/peptides, including physical adsorption, chemical reaction, or biological interaction. BioVenic offers all three approaches to immobilize veterinary therapeutic proteins and peptides, supporting high-throughput screening processes.

Fig.2 Methods for immobilizing peptides in arrays. (Balasaheb, et al., 2014) Fig.2 Immobilization methods for peptide array.^1,2

Other technologies
BioVenic also provides other advanced technologies in HTS for identifying veterinary proteins and peptides, including fluorescence resonance energy transfer (FRET), enzyme-linked immunosorbent assays (ELISA), and mass spectrometry (MS), surface plasmon resonance (SPR), high-content screening (HCS). These techniques collectively facilitate the thorough evaluation of therapeutic candidates by assessing their biological activity, binding affinities, and functional properties, thereby accelerating the discovery and development of veterinary therapeutics for diverse applications including livestock, poultry, aquaculture, companion animals, and economic insects.

High Throughput Screening Service Workflow

Our technology platform encompasses target-based HTS, receptor-based HTS, multiple screening models, and extensive libraries of compound samples and activity data. After consultation, we identify targets based on the client's specific needs. Our experts then design customized biochemical HTS assays according to different targets or receptors. Following this, a comprehensive hit screening using our compound libraries is performed to discover candidate proteins or peptides with high efficacy and stability. Finally, we conduct detailed analyses and provide a thorough report to the client.

Fig.3 The workflow for the high-throughput screening platform for therapeutic protein and peptide discovery. (BioVenic Original) Fig.3 The service workflow of therapeutic protein and peptide discover high-throughput screening platform. (BioVenic Original)

Related Research

A live-cell, structure-based high-throughput screening (HTS) methodology utilizing time-resolved fluorescence resonance energy transfer (TR-FRET) was established to directly target challenging protein-protein interactions (PPIs) within their physiological membrane environment. Using human embryonic kidney 293 (HEK293) cells co-expressing a GFP donor-tagged cardiac sarcoplasmic reticulum Ca²⁺-ATPase (GFP-SERCA2a) and an RFP acceptor-tagged phospholamban (RFP-PLB) in the endoplasmic reticulum, the platform measures real-time conformational and distance changes using a fluorescence lifetime microplate reader. Small-molecule library screening identified 21 hit compounds (>3 SD threshold), with 10 hits reproducibly altering SERCA2a-PLB complex structure and function. Notably, hit characterization revealed isoform-specific functional modulation, increasing SERCA2a calcium affinity in cardiac membranes without affecting skeletal muscle preparations, thereby demonstrating the platform's capacity to isolate target-specific PPI modulators for therapeutic discovery against previously intractable cellular targets.

Fig. 4 Ca-ATPase activity. (Stroik, 2018) (OA Literature) Fig. 4 Ca-ATPase activity for SERCA inhibitors.³

Why Choose Us?

Utilizes advanced high throughput screening technology to rapidly process large quantities of samples, significantly improving the efficiency and speed of screening veterinary therapeutic proteins and peptides.

Microarray technology boasts high sensitivity and specificity, ensuring that even very low abundance proteins and peptides can be accurately detected and analyzed.

Offers a variety of high throughput screening assay services, including cell-based screening and molecular binding assays, to accommodate different types of targets.

Case Study

BioVenic ran a primary high-throughput screening campaign that triaged a diversified veterinary therapeutic peptide library in 96-well plate format. Edge controls gated every plate against a validated baseline, and the normalized plate heat-map clearly separated high-signal positive controls, low-signal negative controls, and a background interior—surfacing a small set of highlighted hit wells. The result was a short, trustworthy hit list ready for confirmation screening, without hand-testing thousands of candidates.

Fig. 5 Case Study (BioVenic Original) Fig. 5 High-throughput Screening

Frequently Asked Questions

Q1: What types of veterinary therapeutic proteins and peptides can be screened using this high-throughput platform?

A: BioVenic's high-throughput screening platform accommodates a wide variety of therapeutic molecules targeting multiple animal species, including pets and livestock. This includes recombinant proteins, monoclonal antibodies, engineered cytokines, and synthetic peptides. For specific target feasibility, complex constructs, or custom molecule types not listed here, please contact our technical support team to discuss tailored assay options for your project.

Q2: What are the sample requirements, purity levels, and quantities needed for high-throughput screening?

A: Sample requirements vary based on the specific library size and assay format (such as binding, cell-based, or enzymatic assays). To prevent assay interference, buffers should be free of toxic preservatives, heavy metals, or excessive detergents. Because exact volume, concentration, and purity thresholds depend on your specific screen, we strongly encourage consulting our technical support team beforehand to receive optimized sample preparation guidelines.

Q3: How do you ensure target species specificity during the screening process?

A: Species specificity is critical in veterinary drug development to ensure efficacy and prevent unwanted cross-reactivity or off-target toxicity. To select the most relevant animal models, tissues, or target orthologs for your specific research goals, please consult our technical support team.

Q4: What assay formats are available, and can custom screening assays be developed?

A: BioVenic offers a broad spectrum of high-throughput assay formats, including biochemical assays (such as ELISA, TR-FRET, and FP) and cellular functional assays (including reporter gene assays, proliferation, and receptor signaling). Our team frequently develops and validates customized assays to match specific client biological mechanisms or therapeutic goals. If your project requires non-standard assay design, specialized cell lines, or specific detection readouts, please get in touch with our technical support team to confirm feasibility and establish an optimized timeline for custom development.

High-throughput screening employs rapid and sensitive detection devices to analyze a large number of samples simultaneously. BioVenic offers HTS services for veterinary therapeutic protein and peptide discovery, identifying biologically active candidates from an extensive library. Our service is designed to accelerate the discovery and development of new drugs for preclinical research, particularly for treating various veterinary diseases. If you need these services, don't hesitate to reach out to us.

References

Nimse, Satish Balasaheb, et al. "Immobilization techniques for microarray: challenges and applications." Sensors 14.12 (2014): 22208-22229. https://doi.org/10.3390/s141222208.
Image retrieved from Figure 1 "Immobilization techniques for fabrication DNA microarray". Nimse, Satish Balasaheb, et al., 2014, used under CC BY 4.0 the title was changed to "Immobilization methods for peptide array".
Stroik, Daniel R., et al. "Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells." Scientific reports 8.1 (2018): 12560. https://doi.org/10.1038/s41598-018-29685-z. Used under CC BY 4.0. Without Modification.